GlassScriptPhysician profile
Laura Milligan
NPI 1275667164
$4,050.07
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,072 · 2022: $823 · 2023: $453 · 2024: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627 · Consulting Fee: $429 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $626.64 |
| Consulting Fee | $429.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $923.76 | 2021-2024 | Jakafi |
| Blueprint Medicines Corporation | $546.03 | 2024 | |
| Servier Pharmaceuticals LLC | $467.50 | 2021 | |
| Celgene Corporation | $460.25 | 2021 | |
| Glaxosmithkline, LLC. | $242.41 | 2022 | |
| Amgen INC. | $189.31 | 2021-2023 | Blincyto |
| Adaptive Biotechnologies Corporation | $132.36 | 2023 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $125.00 | 2022 | |
| Genzyme Corporation | $124.51 | 2021 | |
| Rigel Pharmaceuticals, INC. | $115.88 | 2021 | |
| Kite Pharma, INC. | $113.52 | 2022 | |
| G1 Therapeutics, INC. | $113.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.92 | 2022 | |
| Janssen Biotech, INC. | $110.27 | 2022 | |
| Myriad Genetic Laboratories, INC. | $109.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $107.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.72 | 2024 | |
| Daiichi Sankyo INC. | $26.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.